1

Rhythm ManagementCardiac Rhythm Management (CRM) and

Electrophysiology (EP)

HRS Update

Joe FitzgeraldExecutive Vice President and President,

Rhythm Management

Ken Stein, M.D.Senior Vice President and CMO,

Rhythm Management

Mark BickelVP Finance & Global Controller,

Rhythm Management

2

Safe Harbor for Forward-Looking Statements

This presentation contains forward‐looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward‐looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward‐looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could differ materially from the expectations and projections expressed or implied by our forward‐looking statements.

Factors that may cause such differences can be found in our most recent Form 10‐K and Forms 10‐Q filed or to be filed with the Securities and Exchange Commission under the headings “Risk Factors” and “Safe Harbor for Forward‐Looking Statements.” Accordingly, you are cautioned not to place undue reliance on any of our forward‐looking statements. We disclaim any intention or obligation to publicly update or revise any forward‐looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward‐looking statements.

3

Rhythm Management Offers a Broad Portfolio of Innovative Products and Solutions in Large Markets

Clinical Evidence

Patient Management

Diagnostics & Monitoring Cardiac Rhythm Management

Modular CRM Systems

Mapping & AblationLeft Atrial Appendage Closure

4

Agenda

• High Voltage Portfolio Update

• Electrophysiology and Rhythmia Commercialization

• HRS Clinical Highlights

5

CRM Next Gen: RESONATE Family of High Voltage Devices4 key feature sets; 1st & only to offer EnduraLife™ & HeartLogic ™

EnduraLife™ Battery Technology

HeartLogic™ Heart Failure DiagnosticsSmartCRT™ Therapy(incl. Multi‐Site Pacing)

MRI Conditional Labeling*21

3 4

Expect U.S. Approval Q4:2017

* Not approved in the U.S.

6

EnduraLife™ Battery TechnologyIndustry leading longevity

“…The case for adopting EnduraLife-powered cardiac resynchronisation therapy-defibrillator (CRT-D) devices for treating heart failure is supported by the published evidence. Extended

battery life is of clinical and patient benefit and associated with fewer replacement procedures. […]EnduraLife-powered CRT-Ds should be considered as an option in people

offered CRT-D devices…”- Excerpt from Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure, published March 2017

Over 8 years of commercial experience and 9 published studies demonstrate the industry-leading performance of

* See Reference #2

* See Reference #3

7

U.S. MRI Conditional Labeling TimelinesLast major market gap (U.S. High Voltage) targeted YE17

TV High Voltage

S-ICD

Low Voltage

2017E 2018+E2016

ACCOLADE MRI ESSENTIO MRI

INGEVITY

CRT-P

EL/MINI ICDs, X4 CRT-Ds

(DYN/INO Family & RESONATE Family)

RELIANCE 4-SITEACUITY X4

RESONATE Family ICDs & CRT-Ds

RELIANCE 4-FRONTACUITY X4

IS1/DF1 Replacement ICDs & CRT-Ds

1.5T

1.5T

EMBLEM & EMBLEM MRI

1.5T

EMBLEM MRI

ACCOLADE MRI ESSENTIO MRI

INGEVITY1.5T

FINELINE II

1.5T

U.S. Estimate: Q4 17

8

SmartCRT™ Therapy Provides 3 Key Feature SetsQuad pole pacing, Smart Delay, and MultiSite Pacing (MSP)

SmartCRT = 3 key CRT-D feature sets that will drive BSX share gains

+ ACUITY™ X4 Lead

SmartDelay™ACUITY™ X4 LeadsLV VectorGuide™

Where to pace

Site of latest activation

Whento pace

Maximize global contractility

How to pace

Options to maximize response

Labeled for up to 13.3 years1

longevity with MultiSite Pacing ON

MultiSite Pacing

9

HeartLogic™: HF Diagnostics with Trending & Alerts Significant “referral-driven” share gain opportunities

HeartLogic™ will be available in the RESONATE family of HV devices

Heart Logic Results:• 70% Sensitivity in Detecting HF Events• 34 Days Median time to HF Event• Only 1.47 Unexplained Alerts per Patient Year

HeartLogic™ Heart Failure Diagnostic Service

Algorithm evaluates risk and changes from patient baseline across multiple parameters

Integrated into a simple index with customizable alert

4

10

HeartLogic™: Improving Patient Care & Driving Share

Clinical Outcomes

Supported by a Robust Program of Clinical Evidence

MANAGE-HFMANAGE-HF

2017 2018 2019 2020

HeartLogic™ RegistryHeartLogic™ RegistryReal World Experience

Reimbursement & Cost-Effectiveness Pilots Reimbursement & Cost-Effectiveness Pilots Economic Outcomes

Improve HF Patient Care

Predictive & Population Analytics

Sensor & Data Management Platforms

Care Coordination

11

Agenda

• High Voltage Portfolio Update

• Electrophysiology and Rhythmia Commercialization

• HRS Clinical Highlights

12

Electrophysiology Portfolio Emerging to Drive Growth > Market

ElectrophysiologyPortfolio

Therapeutic Catheters

EP Recording Systems

Mapping and Navigation

Diagnostic Catheters RHYTHMIA HDx™

MAPPING SYSTEMRHYTHMIA HDx™ MAPPING SYSTEM

INTELLAMAP ORIONMapping CatheterINTELLAMAP ORIONMapping Catheter

Navigation & MIFIAblation CathetersNavigation & MIFIAblation Catheters

LAB SYSTEM PROrecording systemLAB SYSTEM PROrecording system

13

RHYTHMIA™ Mapping SystemDriving Placements & Share Gains

5x fasterMAPPING5

25x theDATA POINTS5

0.01mVNOISE THRESHOLD5

Setting the Standard in High Definition Mapping

Active in > 25 countries, with more slated to launch over the next two years

>50 Peer-ReviewedJOURNAL ARTICLES

>10,000 WorldwideCASES

Exponentially more data

See detail never seen before

More accurate and complete mapping

14

Agenda

• High Voltage Portfolio Update

• Electrophysiology and Rhythmia Commercialization

• HRS Clinical Highlights

15

Broad Portfolio of Compelling BSX Data at HRSS-ICD, CRT-D & ICD, Watchman™ and EP products highlighted

Thursday, May 11

S‐ICD SystemLate‐Breaking Clinical Trial: The S‐ICD Post‐market Approval Study: Michael R. Gold, M.D., Ph.D, FHRS, will present at 8:00 AM in room 375E.

Evaluation of an Automatic Screening Tool for S‐ICD Patient Selection: A poster authored by Venugopal Allavatam,MS, will be available for viewing from 9:30 AM ‐12:00 PM in Epicenter, Exhibit Hall.

CRT‐D and ICDRight Ventricular Lead Location, Right‐Left Ventricular Lead Interaction, and Long‐Term Mortality in Cardiac Resynchronization Therapy Patients: Usama Daimee, M.D., will present at 2:30 PM in room 186.

Multiple Procedures Increase the Risk of Infection but Not Mechanical Complications in Patients with Implantable Cardiac Defibrillators: Jayanthi N. Koneru, MBBS, will present at 2:45 PM in Room 375D.

Friday, May 12

WATCHMAN LAAC DeviceLate‐Breaking Clinical Trial: EWOLUTION trial: 1‐Year Efficacy and Safety of Left Atrial Appendage Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation: Lucas V. A. Boersma, M.D., Ph.D, will present at 11:00 AM in Room 375E.

S‐ICD SystemChronic performance of Communicating Leadless Anti‐Tachycardia Pacemaker and Subcutaneous Implantable Cardioverter Defibrillator: Fleur V.Y. Tjong, M.D., will present at 1:30 PM in Room 375D.

Propensity Score Matched Comparison of Subcutaneous and Transvenous Implantable Defibrillator Therapy in the SIMPLE and EFFORTLESS studies: A poster authored by Tom F. Brouwer, M.D. and Jeffrey S. Healey, M.D., FHRS, will be available for viewing from 2:00 PM – 5:00 PM in Epicenter, Exhibit Hall.

CRT‐D and ICDExtended Follow‐Up of a Family of Anatomically Designed Quadripolar Left Ventricular Leads: A poster authored by Suneet Mittal, M.D., FHRS, will be available for viewing from 2:00 PM – 5:00 PM in Epicenter, Exhibit Hall.

Electrophysiology*Local impedance via mini electrodes successfully measures catheter‐tissue contact and is strongly correlated to radiofrequency lesion dimensions in explanted swine hearts: A poster authored by Matthew S. Sulkin, Ph.D, will be available for viewing from 2:00 PM – 5:00 PM in Epicenter, Exhibit Hall.

Local impedance via mini electrodes as an in vivo indicator of catheter‐tissue coupling and lesion maturation: Jacob I. Laughner, Ph.D., will present at 3:15 PM in Epicenter, Exhibit Hall.

*over 18 independent abstracts on the Rhythmia™Mapping System

16

WORLD’S LARGEST PROSPECTIVE STUDY OF THE S-ICD SYSTEM

HRS LBCT, Thursday May 11th, 8:00 am, Dr. Michael Gold

Largest S-ICD study to date

1637 patients from 86 centers in the US

Population more similar to TV-ICD populations, and higher comorbidities

“Mainstream” indications: 66.6% Primary Prevention, low EF patients

Excellent Acute Outcomes

98.7% success in acute conversion of VT/VF arrhythmias

Complication-free rate of 96.2% at 30 days

S-ICD Post-Approval Study: LBCT 5/11 8:00am“Mainstream” indications and excellent acute outcomes

17

First report of efficacy results from the EWOLUTION Prospective

Registry at 2 Late-Breaking Clinical Trial Sessions

HRS Friday, May 12th, 11am* Chicago, IL USA

EuroPCR Thursday, May 19th, 11:47am* Paris, FRANCE

EWOLUTION Registry: >1000 patients, 47 centers in 13 countries

Throughout Europe, the Middle East, and Russia

HRS: 1-year outcomes in the overall trial population

EuroPCR: Results in the warfarin-ineligible cohort

focusing on treatment options in these patients

WATCHMANTM LAAC: LBCT 5/12 11:00am EWOLUTION Prospective Registry – data at HRS & EuroPCR

18

References

Reference #1 Assumes: 2.0V RA, LV-only, 2.0V LVa, 2.0V LVb, 700Ω, No LATITUDE, No Respiratory Rate Sensor, No Heart Failure Sensor Suite

Reference #2 Landolina M, Curnis A, Morani G, Vado A, Ammendola E, D’onofrio A, Stabile G, Crosato M, Petracci B, Ceriotti C, Bontempi L, Morosato M, Ballari GP, Gasparini M. Longevity of implant Cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer. Europace2015;17:1251-58. doi:10.1093/eurospace/euv109. First published online: May 14, 2015. Medtronic = 532 patients, Boston Scientific = 291 patients, St. Jude Medical = 106 patients, Biotronik = 20 patients, Sorin = 69. Five-year survival rate of latest marketed devices (between 2006 to 2010) calculated using device replacements for battery depletion as indicated by ERI.

Reference #3 1. Haarbo J, Hjortshoj S, Johansen J, Jorgensen O, Nielsen J, Petersen H. Device Longevity in Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators Differs Between Manufacturers: Data from the Danish ICD Registry. Presented at HRS 2014. http://ondemand.hrsonline.org/common/presentation-detail.aspx/15/35/1241/9000. Boston Scientific = 136 patients, Medtronic = 651 patients, St. Jude Medical = 1,587 patients, Bitronik = 369 patients. Time to exchange of the device because of battery depletion or device failure recorded in the Danish ICD Registry was the endpoint. The four-year survival rate for devices in the Danish Registry study was 81.1% for Medtronic and 95.7% for Boston Scientific (P<0.01).

2. J. Williams, R. Stevenson. Contemporary cardiac resynchronization implantable cardioverter defibrillator battery longevity in a community hospital heart failure cohort. Presented at HFSA 2014. http://www.onlinejcf.com/article/. S1071-9164(14)00389-3/fulltext. Boston Scientific = 53 patients, Medtronic = 28 patients, St. Jude Medical = 10 patients. Four-year survival rate calculated using device replacements for battery depletion as indicated by ERI.

3. Ellis CR, Dickerman DI, Orton JM, Hassan S, Good EG, Okabe T, Andruilli JA, Quan KJ, Greenspon AJ. Ampere Hour as a Predictor of Cardiac Resynchronization Defibrillator Pulse Generator Battery Longevity: A Multicenter Study. PACE 2016 doi: 10.1111/pace.12831 first published online 11-MAR-2016. The five major institutions performing the study include, at Vanderbilt University, Henry Ford Hospital, University of Michigan, Thomas Jefferson University, Cooper Health System, North Ohio Heart Center. Boston Scientific = 322 patients, Medtronic = 794 patients, St. Jude Medical = 186 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.

4. Landolina M, Curnis A, Morani G, Vado A, Ammendola E, D’onofrio A, Stabile G, Crosato M, Petracci B, Ceriotti C, Bontempi L, Morosato M, Ballari GP, Gasparini M. Longevity of implant Cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer. Europace2015;17:1251-58. doi:10.1093/eurospace/euv109. First published online: May 14, 2015. Medtronic = 532 patients, Boston Scientific = 291 patients, St. Jude Medical = 106 patients, Biotronik = 20 patients, Sorin = 69. Five-year survival rate of latest marketed devices (between 2006 to 2010) calculated using device replacements for battery depletion as indicated by ERI.

5. Zanon F, Martignani C, Ammendola E, Menardi E, Narducci ML, De Filippo P, Santamaria M, Campana A, Stabile G, Potenza DR, Pastore G, Iori M, La Rosa C, and Biffi M. Device Longevity in a Contemporary Cohort of ICD/CRT-D Patients Undergoing Device Replacement. Doi:10.1111/jce.12990, First published online 20-APR-2016. Comparison of device longevity by Kaplan-Meier curves of CRT-D systems extracted between March 2013 and May 2015. Medtronic = 195 patients, Boston Scientific = 157 patients, St. Jude = 72, Biotronik = 9.

6. Provided by Dr. Ernest Lau on 04/29/15 in support of Lau E, Wilson C, Ashfield K, McNair W, McEneany D, Roberts M, Large Capacity LiMnO2 Batteries Extended CRTD Longevity in Clinical Use Compared to Smaller Capacity LiSVO Batteries Over 6 Years. Presented at HRS 2015. Medtronic = 62 patients, Boston Scientific = 27 patients, St. Jude = 66 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.

7. von Gunten S, Schaer BA, Yap SC, Szili-Torok T, Kühne M, Sticherling C, Osswald S, Theuns DA. Longevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time. Europace. 2015 Nov 25; . Epub 2015 Nov 25. Total patients = 3436.

8. Alam MB, Munir MB, Rattan R, Adelstein E, Jain S, Saba S. Battery longevity from cardiac resynchronization therapy defibrillators: differences between manufacturers and discrepancies with published product performance reports. Europace 016;doi:10.1093/europace/euw044. First published online: 22-MAR-2016. Kaplan Meier curves depicting survival of CRT devices free from battery depletion by device manufacturer. Battery Longevity in Cardiac Medtronic = 416 patients, Boston Scientific = 173 patients, St. Jude Medical = 57patients. Previously evaluated these patients at a four-year survival rate calculated using device replacements for battery depletion as indicated by ERI. 2014; Europace (2014) 16,246-51.

9. Shabanna Din, Shabanna, Mcgee, Rao, Archana, Wright, Jay D. Longevity of implantable cardioverter defibrillators: The impact of device manufacturer and device type on device longevity were assessed. Europace. 2015 Nov 25; . Epub 2015 Nov 25. Total patients = 3436. Cardiostim Abstract 2016. Total patients = 1489.

19

References

Reference #4Boehmer et al. A Multisensor Algorithm Predicts Heart Failure Events in Patients With Implanted Devices. Results from the MultiSENSE Study. JACC: Heart Failure. Volume 5 Issue 3. March 1, 2017

Reference #5Based on approximate mapping speed of 95 pts / minute in the right atrium in 5 swine USING THE ST. JUDE PRECISION ENSITE MAPPING SYSTEM. Ptaszek LM, et al. “Rapid High-Density Automated Electroanatomical Mapping Using Multiple Catheter Types.” Poster Session PO097 APHRS 2015.Based on approximate mapping speed of 491 pts / minute in the right atrium in 5 swine USING THE BOSTON SCIENTIFIC RHYTHMIA MAPPING & NAVIGATION SYSTEM. Ptaszek LM, et al. “Rapid Acquisition of High-Resolution Electroanatomical Maps Using a Novel Multielectrode Mapping System.” JICE. Nov 2012.C1. Ptaszek L, Chalhoub F, Perna F, Beinart R, Barrett C, Danik S, Heist EK, Ruskin J, Mansour M, Rapid Acquisition of High-Resolution Electroanatomical Mapping Using a Novel Multi-Electrode Mapping System. J Interv Card Electrophysiol. 2012 Nov 22

20

Rhythm Management Offers a Broad Portfolio of Innovative Products and Solutions in Large Markets

Clinical Evidence

Patient Management

Diagnostics & Monitoring Cardiac Rhythm Management

Modular CRM Systems

Mapping & AblationLeft Atrial Appendage Closure